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Summary We describe physical function in adults with osteogenesis imperfecta (OI) and explored 
clinical and non-clinical factors related to its impairment. Our data showed that physical dysfunction 
is a common feature of adults with OI, varying by OI severity, and mediated by the presence and 
quality of pain and fatigue symptoms.  
Introduction There is a paucity of data describing physical function in adults with Osteogenesis 
imperfecta (OI). We investigated the effects of OI and its severity on physical function, and explored 
the relationship between physical function and number of fractures and symptomatology. 
Methods Adults with OI of different types were recruited from the RUDY study, an ongoing UK-
based prospective cohort study. Participants completed demographic and clinical questions, and 
questionnaires. These assessed physical function (SF-36), mobility (EQ-5D-5L and NEADL), fatigue 
(FACIT-F) and pain (SF-MQ-2). Scores were compared using parametric or non-parametric statistical 
analyses, whereas correlations between outcomes were examined using univariate and multivariate 
regression analysis. 
Results Seventy-eight adults with OI aged 43.5±14.5 years were enrolled (type I, 32; type III, 11; 
type IV, 10; unknown type, 26). Physical function (PCS, SF-36) was significantly lower in all 
participants than normative values (p<0.001) and in type III than type I (p=0.008). Mobility was 
significantly different across the types (EQ-5D-EL, p=0.007; NEADL, p<0.001), with type III having 
more severe problems, followed by types IV, unknown and I. Physical function was associated with 
OI type (r=0.26; p=0.021), presence and quality of pain (r=-0.57; p<0.0001) and fatigue (r=-0.51; 
p<0.0001). Multivariate analysis revealed that physical function correlated independently with age, 
OI type, fatigue and non-neuropathic pain. 
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Conclusions Individuals with OI display a marked deterioration in physical function during 
adulthood. This impairment varies in severity according to the OI phenotype and is associated with 
































         Osteogenesis imperfecta (OI) is a genetic skeletal disorder, characterised by qualitative 
and quantitative abnormalities of type I collagen[1]. In approximately 80% of individuals with OI, a 
mutation in one of the COL1A1 or COL1A2 genes is believed to be responsible for the disorder1. 
Although the incidence of OI varies globally, it has been estimated to occur in 1 in 10,000 to 1 in 
20,000 births. In the United Kingdom, it has been reported that approximately 3,400 individuals have 
this condition[2].  
 The main clinical feature of OI is decreased bone mineral density and bone fragility, leading 
to a high incidence of fractures, particularly in childhood[1]. The chronic sequelae of fractures also 
causes a higher incidence rate of osteoarthritis and skeletal deformities, predisposing the patient to 
chronic pain[3]. Such extreme debilitating symptoms, in concert with fatigue, may be linked to 
physiological stress and physical inactivity[4]. As a consequence, the clinical condition of people 
with OI is related to both disease and inactivity.           
Among the array of OI clinical features, musculoskeletal manifestations are the main 
determinants of physical deterioration and quality of life (QoL). There is also a growing body of 
evidence suggesting that OI patients display lower muscle strength and power and greater 
fatigability[5]. These characteristics are associated with reduced muscle mass and quality (i.e. 
strength per unit of  muscle mass)[5].                                                 
            While the effect of OI on physical function has been largely explored in children and 
adolescents, limited investigations have been conducted in adults[6–8]. Among this cohort, the impact 
of OI on physical function remains poorly described, with no investigations conducted on the UK 
adult population. Additionally, there is no uniformity of evidence about the relationship between the 
OI type and severity of physical function impairment.           
            Our aim was to describe in adults with OI, the differences in physical function by OI type and 
the relationship between physical function and history of fractures, pain and fatigue symptoms. We 
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hypothesise that physical function is impaired in people with OI during adulthood according to its 




       This cross-sectional analysis used data from the Rare and Undiagnosed Diseases Study (RUDY 
study), an ongoing UK-based multi-centre prospective cohort study, aimed at improving the 
understanding of rare diseases affecting musculoskeletal systems[9].  Data were collected using a 
web-based registry and patient-driven research platform. The RUDY web-platform has been 
previously described[9]. Briefly, patients gave online dynamic consented using the RUDY website 
(www.rudystudy.com) and were then given access to their own password-protected website that 
included validated questionnaires and forms for the participant to record OI type and medical events 
(i.e. number of fractures). Participants were invited every six months to complete questionnaires 
through email messages sent from the RUDY platform.   
        For this analysis, inclusion criteria were a self-reported diagnosis of OI from participants aged 
18 or over and completed baseline questionnaires.  
 
Patient-reported outcome measures 
       Participants were asked to respond to general questions regarding demographic information, OI 
type, and the number of fractures during their lifetime. Participants self-reported their OI type if 
known, but were also able to select type ‘unknown’. Self-reported questionnaire-based methods are 
accurate for the assessment of fractures, particularly for those occurring at the clinically-relevant hip 
and distal radius sites [10]. In addition, participants were asked to complete five questionnaires: 
general health status (The Short-Form 36 health survey (SF-36) and the EuroQol five-dimensional 
questionnaire (EQ-5D-5L), fatigue (The functional assessment of chronic illness therapy fatigue 
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(FACIT-F), pain (Short-Form McGill Pain Questionnaire 2 (SF-MPQ-2) and functional performance 
during daily living activities (Nottingham Extended Activities of Daily Living (NEADL). 
The SF-36 version 1.0 questionnaire is composed of 36 items measuring four domains of 
physical function, four domains of mental status, and is completed with reference to the previous four 
weeks[11]. Scoring ranges from 0 which corresponds to the worst possible status, to 100 which is the 
best possible status. Physical and mental domains are combined to calculate the physical component 
score (PCS) and mental component score (MCS)[11]. Scores were generated by multiplying each SF-
36 scale z-score, by its respective physical factor or mental component scoring coefficient, and 
summing the eight products. Reference values and scoring coefficients were based on general UK 
population data provided by Jenkison et al[12, 13]. The component scores were then transformed so 
that each had a mean of 50, and a standard deviation (SD) of 10. The SF-36 version 1.0 provides six 
response levels to question 21 (bodily pain), whereas only five options, with the exclusion of “very 
mild”, were shown to participants in our web-form. We therefore randomly allocated the 22 
participants answering “mild” into two groups, corresponding to response levels of “very mild’ and 
“mild”, respectively, and thereafter calculating scores according to the traditional procedure.  
            The EQ-5D-5L instrument describes health-related QoL in terms of five dimensions: mobility, 
self-care, usual activities, pain/discomfort and anxiety/depression[14]. Each dimension has five levels 
of functioning: (1) no problems; (2) slights problems; (3) moderate problems, (4) severe problems 
and (5) unable/extreme problems. For a better understanding, response levels for each dimension are 
presented in the manuscript divided into three categories: `no and slight problems` (levels 1 and 2), 
`moderate` (level 3) and, `severe and extreme problems` (levels 4 and 5). Reference values were 
based on UK population data[15]. 
The SF-MPQ-2 tool characterises pain quality and intensity[16]. It consists of 22 items 
grouped into four dimensions (continuous, intermittent, neuropathic and affective pains). Each item 
is rated based on a 0–10 scale, where 0 is ‘no pain’ and 10 is ‘worst pain’. Continuous and intermittent 
scores were combined to assess non-neuropathic pain. Three scores (neuropathic, non-neuropathic 
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and affective) were calculated from the mean of the items included in each dimension and a total 
score by the mean of all items.   
FACIT-F assesses the fatigability of different domains including physical, social/family, 
functional, wellbeing and additional concerns[17]. It uses a five-point Likert scale (0 = ‘not at all’ to 
4 = ‘very much’). Item scores were transformed based on FACIT guidelines and then combined to 
obtain a total summative score, with higher scores reflecting a lower fatigue level. The value set for 
the USA was used as normative data[18]. 
 NEADL quantifies (22 items of) functional independence in four areas: mobility, kitchen, 
domestic and leisure[19]. The scores of each item were combined to give four subscales scores, while 




          Data were expressed as the mean ± SD for parametric variables, median and interquartile range 
(IQR) for nonparametric data, and percentages for categorical variables. All parameters were tested 
for normal distribution by visual inspection and Kolmogorov-Smirnov test. Differences among the 
OI groups in terms of age, number of fractures and scores from SF-36, NEADL, FACIT-F and SF-
MPQ-2 questionnaires were assessed using analysis of variance (ANOVA) for parametric variables, 
or the corresponding Kruskal-Wallis tests for nonparametric continuous variables, and the χ2 test for 
categorical variables. When indicated, the Tukey’s (parametric) or Dunn’s (nonparametric) post hoc 
tests for multiple comparisons were applied.  
Analysis of covariance (ANCOVA) was used to test differences in number of fractures among 
the OI groups after adjusting for age. Comparisons between SF-36, FACIT-F and EQ-5D-5L scores 
and normative data were performed using one-sample t tests. Fisher’s exact tests were performed to 
assess differences among OI types on the proportion of participant responses for each category of the 
EQ-5D-5L questionnaire.  
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          Univariate correlation analyses between PCS and age, number of fractures, presence and 
quality of pain (non-neuropathic, neuropathic and affective pain), and fatigue were performed using 
Pearson’s or Spearman’s rho test. Multivariate linear regression analyses with stepwise backward 
selection were applied to assess independent correlates of PCS. Covariates were age, OI type, sex, 
number of fractures, fatigue and quality of pain. Regression imputation following the EM algorithm 
was used to replace 24 missing values of the variable ‘number of fractures’. This data was then 




          Of the 150 adults with OI (47 males, 103 females, aged 42.8±14.5 years) who were recruited 
into the RUDY study, 78 individuals (20 males and 58 females), with a mean age of 43.5±14.5 years, 
fully completed all questionnaires (response rate of 52%). Adults with OI who did not complete the 
questionnaires included 27 males and 45 females, with a mean age of 42.1±14.5 years and different 
types of OI (29 type I, 11 type III, 4 type IV, 3 type V and 25 unknown type).  No differences were 
found in age, sex, or OI types distribution among people who did and did not complete the 
questionnaires.  
          The clinical characteristics of study participants are shown in Table 1. Thirty-two (41%) 
individuals reported a diagnosis of OI type I, 10 (12.8%) of type III, and 10 (12.8%) of type IV and 
26 (33.3%) an unknown type. Participants with OI type III were younger (34.6±11.3 years) than those 
with type I (45.7±14 years; p=0.025) and unknown type (45.9±14.6 years; p=0.039), whereas no 
difference was observed with participants with type IV (40.7±18.8 years; p=0.392).  
     Fifty-four adults with OI (response rate of 69.2%) provided information on the number of fractures 
during their lifetime (Table 1). From these participants, an average number of 26 (SD ±20.4) fractures 
per participant were reported in individuals with type III; 13 (SD ±8.7) in those with type I; 11.2 (SD 
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±12.4) in those with type IV; and 16.5 (SD ±23.5) in those with unknown type. Although there were 
large differences among the OI groups these were not statistically significant. 
 
Health status and functional independence 
         Table 2 shows the physical domains and PCS scores from the SF-36 questionnaire. The 
mean values from physical domains and PCS scores were significantly lower in all participants, when 
compared to normative UK values (p<0.05). Among the OI types, participants with OI type I had 
significantly higher mean physical function (PF) values than those with III (p<0.001), IV (p=0.038) 
and unknown OI types (p=0.004), whereas only PCS was higher than those with type III (p=0.008). 
There were no statistically significant differences in the other outcome measures. Table 3 shows the 
total and subscale ADL scores according to the OI types. Participants with types III and IV had severe 
problems or were unable to perform most of the mobility and domestic tasks. Individuals with type I 
reported no problems or only mild problems performing most activities, whereas those with type 
unknown only had severe difficulties during domestic activities. Comparisons among the groups only 
showed significantly lower scores for mobility and domestic tasks among individuals with type III 
compared with those with type I (p < 0.001).  
      Figure 1 shows the response level frequencies from the EQ-5D-5L questionnaire. Adults with OI 
reported more problems in mobility and usual activities and had more frequent pain symptoms than 
the general UK population (p<0.05). Self-care problems were more common in participants with 
types III (p<0.001), IV (p=0.023) and unknown (p=0.009), whereas Anx/Depres was more frequent 
in types IV (p<0.001) and unknown (p=0.005) than the general UK pupulation. Among OI types, 
severe/extreme mobility problems were most commonly reported by adults with OI type III, followed 
by those with type IV, unknown type, and type I. Moderate mobility problems were reported by 
approximately 20% of participants with types III, IV and unknown, whereas a lower percentage of 
participants with type I reported such problems. Self-care was reported as not being/a slight problem 
for most participants with OI types I, IV, and unknown. This was in contrast to more than half of 
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adults with type III who identified self-care as a problem. The majority of participants with type I 
indicated no/slight problems when performing usual activities. Severe/extreme problems were more 
frequent in individuals with type III, while moderate problems were more commonly reported in those 
participants with an unknown type. A similar percentage of participants in all groups reported 
severe/extreme pain, whereas moderate levels were most commonly found in type III patients, 
followed by types IV, unknown and I. Anxiety/depression was the least problematic issue for 
participants, with only a small proportion of respondents of all groups detailing severe or extreme 
anxiety/depression problems. The Fisher`s exact test detected significant differences among OI types 
in responses for the mobility (p=0.007) and self-care (p=0.049) dimensions and no differences for 
pain/discomfort (p=0.235) and anxiety/depression (p=0.384).  
 
Pain and fatigue  
         Mild levels of neuropathic, non-neuropathic and affective pains were reported by all participants 
(Table 1). Non-neuropathic (p=0.005) and affective (p=0.002) pain scores were significantly higher 
than neuropathic pain. No significant differences were detected in subscales and total pain scores 
among OI types.  
The FACIT-F score (Table 1) was significantly lower in all participants compared with the USA 
normative values (p < 0.001). Although there were large differences across the OI types these were 
not statistically significant. 
 
Correlations 
         Univariate analysis (Table 4) revealed that PCS was correlated with FACIT-F score (fatigue), 
and inversely with OI types, and non-neuropathic, neuropathic, affective and total pain scores. No 
correlation was found between PCS and age, sex and number of fractures. After adjusting for 
covariates, multivariate analysis (Table 4) showed that PCS was independently correlated with OI 





      To the best of our knowledge, this is the first study to describe physical function in a cohort of 
UK adults with OI and across different OI types, and more specifically the first to assess associations 
between clinical problems such as fractures, pain and fatigue and deficits in physical function. The 
most salient results show that the impairment of physical function is a typical feature of adults with 
OI, which differs between OI types. Independent of this type-specific variation, specific symptoms 
such as non-neuropathic pain and fatigue are associated with lower physical function. These findings 
support the concept that phenotype and symptomatology contribute independently to the loss of 
functional independence in OI.  
      Although insufficient study power may have limited the capacity to detect differences in some 
parameters across the OI types, our data suggest that impaired physical function, and in particular of 
mobility affects individuals with OI type III, followed by those with type IV and then type I.  These 
findings are confirmed by the association reported by multivariate analysis which revealed that OI 
type is an independent correlate of the impairment of physical function in OI. These results are in line 
with several studies exploring the effects of OI on surrogate measures of physical function in 
populations of different age. There is evidence showing that OI type is the most important determinant 
of the physical performance in childhood, adolescence and young adults [20,21]. A recent study 
conducted in a Danish adult population showed that  physical health  varies  according to the type of 
OI, with marked impairment in people with type III than other types [4]. Taken together, findings 
from the present and previous studies support the hypothesis that individuals with OI are characterised 
by an impairment of physical function which persists across the lifespan, and the severity of 
functional impairment is dependent on OI type. The marked differences in physical function across 
the OI types likely result from the wide array of clinical manifestations (i.e. growth deficiency, degree 
of skeletal dysplasia and frequency of fractures) which vary significantly in both presence and 
severity according to the phenotype [1,2].  
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    Since we reported large differences between physical outcomes and general UK population, we 
also suggest that physical function could be more markedly impaired than previously assumed. In 
particular, adults with type I reported an approximatively 25% lower physical function and mobility 
compared with the UK general population. These findings suggest that not only “moderate and 
severe” forms but also  “mild” of OI determine marked impairment in physical performance during 
adulthood. However, more accurate measures need to be performed to quantify the amount of 
difference in physical function between healthy and OI adults. Although there is evidence showing a 
comparable level of function between types I and IV, our data promote the concept that individuals 
with type IV had values of physical function between types III and I [7, 21]. Since age and assessed 
measures were similar across the studies, it is possible that differences in lifestyle and health care 
between different study populations (USA vs UK) might have mediated this discrepancy.  
       In addition to OI type, our work is the first characterising the role played by fractures and specific 
symptoms such as fatigue and pain. Multivariate analysis, after accounting for covariates and missing 
data, showed the absence of association between the number of fractures and physical performance, 
thus suggesting that other factors may contribute to the high level of physical impairment in OI. 
Although this finding is difficult to reconcile with the extreme debilitating sequelae induced by 
fractures including, fear of fractures, pain and deformities, it is possible to hypothesise that the 
number of fractures could play a lesser role in the development of physical alterations than that 
reported in children. This could be related to the lower incidence of fractures[1] during adulthood 
than childhood, which might result in a longer recovery time and consequently in a partial restoration 
of the physical function and alleviating of the psychological distress. 
       Although it is well recognised that pain is an extremely debilitating symptom of OI responsible 
for the impairment of physical performance, we were the first to investigate the role played by the 
type of pain through the characterisation of the effect of non-neuropathic and neuropathic pain. Our 
data show that, although both types of pain are strongly associated with physical function (univariate 
correlation), only non-neuropathic pain was independently correlated (multivariate analysis) with 
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physical function. Thus, we suggest that the quality of pain has a determinant role in the development 
of physical disability in adults with OI. Since only mild levels of pain were reported by the 
participants, we also suggest that chronic pain, independent of severity, has the capacity to induce 
severe functional deficits in OI. Our data shows that adults with OI have a higher level of fatigue than 
healthy individuals, and the severity of this symptom is not related to OI phenotype. These findings 
are in line with a recent study conducted in a Netherlands adult cohort with OI documenting high 
levels of fatigue performing several daily living activities[22]. This evidence supports the notion that 
fatigue is a common symptom in OI which plays a determinant role in the loss of physical function, 
highlighting the necessity to prevent or treat the symptom to counteract physical dysfunction in OI.                                     
        One potential impact of these findings is to highlight the importance of incorporating exercise 
into the care of adults with OI. Exercise training  is the only strategy that has the potential to elicit 
multiple beneficial effects at  the metabolic, cardiovascular, muscular and skeletal levels[23]. There 
is also evidence showing that exercise can alleviate pain symptoms and improve physical and 
physiological aspects related to the increased fatigability[24]; altogether, these adaptations showed 
the potential role of exercise on  improving  physical and mental health and therefore QoL for people 
with OI.  Although the effects of exercise have been well documented  in several clinical populations, 
currently the evidence available in OI has been gathered only in children and adolescents[25], thus 
there remains lack of information on the safety and effectiveness of exercise training for counteracting 
physical dysfunction and symptomatology in adults with OI and training for specialist 
physiotherapists and other allied health professionals.   
       This study presents several strengths and limitations. Its main strengths are the inclusion of 
participants with different OI types and the characterisation of physical function and symptomatology 
through the use of different validated tools. Limitations include the accuracy of self-reported 
measures, the partial specificity of the questionnaires used to explore physical function and symptoms 
in OI, the lack of a healthy control group and the cross-sectional design of the study, which did not 
allow assessment of the causal relationship between OI type, symptomatology and physical 
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dysfunction.  There are currently no OI-specific questionnaires for physical function, mobility and 
pain, and future development of OI-specific instruments is warranted. A minority of patients self-
reported fractures which, combined with the substantial within-group variation in fracture incidence, 
may have limited our ability to detect group differences or associations with physical function. 
Individuals with OI self-reported their OI type in line with previous questionnaire-based studies, and 
we included an option for ‘unknown’ type for those who were uncertain.  Despite this, there remains 
the possibility that individuals misreported their OI type which would decrease our power to detect-
group differences.  In addition, a conservative method of statistical analyses was applied which may 
have limited our power to detect moderate differences in outcomes between individuals with different 
OI types.  There was a geographical discrepancy between our SF-36 version and the UK version 
[12,13] used to calculate scores for mental components, but as our study aims focused on physical 
rather than mental health this would not influence the main findings.  Additionally, insufficient study 
power has limited the capacity to detect differences in some parameters. However, it is important to 
note that the small numbers of participants in types III and IV reflect not only the rarity of OI, but 
also the lower incidence of these types, which makes their enrolment even more complicated. As 
RUDY participants are self-selected, we cannot guarantee that it is representative of the OI population 
in the UK; however, it is the largest cohort of its type in the country and provides the best evidence 
possible to answer the questions we set out to examine. Finally, the response rate in our study was in 
line with previously published questionnaire-based studies, and assessment of participant 
characteristics of those individuals who did and did not complete the questionnaires were similar.  
Despite this, the limited numbers of responders and possible self-selection bias may also affect the 
generalisability of our findings.  
      In summary, this study reports cross-sectional data from a large cohort of the UK adults with OI, 
showing that the severity of physical impairment varies according to OI type. The presence and 
quality of specific symptoms such as non-neuropathic pain and fatigue are factors which contribute 
significantly to the development of such deficits. Specific countermeasures should be included in the 
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standard care of adults with OI to prevent and counteract the loss of physical function and to alleviate 
pain and fatigability symptoms. 
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            Data expressed as mean ± standard deviation or median and interquartile range as appropriate.  
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 All I IV III unknown 
 
p values 
Sample size (n) 78 32 10 10 26  




Age (range years) 18 - 75 21 - 71 22 - 73 24 - 65 21 - 75  
Gender, m/f  (n) 20/58 8/24 2/8 3/7  7/19  
Fractures (n) 15.4±16.6 13.2±8.7 11.1±12.4 26±20.4 16.5±23.5 0.295 
McGill pain scores        
Non-neuropathic 1.62 (0.81; 3.08) 1.70 (0.52; 3.02) 1.16 (0.56; 2.22) 1.54 (0.54; 4.28) 1.91 (1.16; 2.88) 0.512 
Neuropathic 1.20 (0.27; 2.55) 0.60 (0.20; 2.70) 0.95 (0.15; 2.47) 1.35 (0.37; 2.35) 1.80 (0.60; 2.72) 0.499 
Affective  1.80 (0.45; 3.12) 1.15 (0.05; 3.25) 1.15 (0.22; 2.82) 2.30 (0.72; 3.20) 2.15 (1.22; 3.62) 0.252 
Total 1.71 (0.74; 2.86) 1.75 (0.43; 2.80) 1.26 (0.54; 1.91) 1.54 (1.12; 3.33) 1.85 (1.12; 3.19) 0.340 
FACIT-Fatigue 33.5 (20.7; 41) 38.5 (29; 44.7) 26 (17.2; 34.5) 33.5 (13.5; 37.5) 25.5 (19; 37.7) 0.068 





                      Table 2 SF-36 physical component and domains scores in OI types and in the general population 


































                     
 type I  UK norm  
 Mean (SD) Mean (SD) p values 
Physical domains    
Physical function 57.3 (28.4) 87.2 (20.9)  <0.001 
Role physical 41.4 (45.1) 83.5 (33.8)  <0.001 
Bodily Pain 55.1 (24.1) 80.7 (25.5) =0.001 
General Health 47 (14) 71.3 (23.4)       =0.001 
Physical component score 37 (9.8) 50 (10)       <0.001 
 type IV UK norm  
Physical domains    
Physical function 32 (27.3) 93.3 (13.4)  <0.001 
Role physical 32.5 (39.1) 88.2 (28)  <0.001 
Bodily Pain 51.9 (23.6) 84.9 (21.8)  <0.001 
General Health 45.2 (15.5) 75.5 (19.5)  =0.001 
Physical component score 29.8 (12.9) 50 (10)  <0.001 
 type III UK norm  
Physical domains    
Physical function 15.5 (10.6) 93.3 (13.4)  <0.001 
Role physical 17.5 (26.4) 88.2 (28) <0.001 
Bodily Pain 40.9 (20.3) 84.9 (21.8)  <0.001 
General Health 50.2 (10) 75.5 (19.5)  =0.001 
Physical component score 25.5 (4.9) 50 (10)  <0.001 
 type unknown UK norm  
Physical domains    
Physical function 31.9 (31.5) 87.2 (20.9)  <0.001 
Role physical 32.7 (40.4) 83.5 (33.8)  <0.001 
Bodily Pain 50 (23.3) 80.7 (25.5)  =0.001 
General Health 49.5 (11.3) 71.3 (23.4)  =0.001 
Physical component score 31.6 (11.1) 50 (10)  <0.001 
1 
 
                     
                 Table 3.   Nottingham Extended Activities of Daily Living scores in people with OI.  
                                 
 
 type I  type IV type III type unknown p values 
Median IQR Median IQR Median IQR Median IQR  
Mobility 6     5-6 3 1-6 1 0-3 5 1-6 <0.001 
Domestic 5 5-5 3.5 2-5 2.5 1-5 3.5 2-5 0.001 
Kitchen 5 5-5 5 4-5 5 2-5 5 3-5 0.316 
Leisure 5 5-6 5 3-5 4 3-5 4 3-6 0.018 

























                         Table 4. Pearson/ Spearman correlation used for univariate analysis and multiple linear regression for multivariate analyses  
 
                      PCS Univariate Analysis                     Multivariate analysis   
Variables Rho p values beta 95% CI p values 
Age -0.114 0.320 -0.226 -0.29, -0.04 0.011 
Gender -0.356 0.545 - - - 
Type of OI -0.262 0.021 -0.309 -5.12, -1.37 0.001 
Number of fractures -0.111 0.426 - - - 
Fatigue score  0.519 <0.0001  0.245 -4.34, -1.64 0.021 
Non-neuropathic pain -0.543 <0.0001 - - - 
Neuropathic pain -0.506 <0.0001 -0.439 0.03, 0.37 <0.0001 
Affective pain  -0.460 <0.0001 - - - 
Total pain score -0.575 <0.0001 - - - 
 
                            PCS: physical component score 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
